

## Key Consolidated Financial Highlights


Alfresa Holdings Corporation and consolidated subsidiaries  
Years ended March 31

	Millions of Yen		Thousands of U.S. Dollars
	2006	2005	2006
<b>For the Year:</b>			
Net Sales	¥1,411,639	¥1,195,314	\$12,017,017
Operating Income	14,847	6,534	126,386
Net Income	7,074	3,208	60,216
<b>At Year-end:</b>			
Shareholders' Equity	¥ 131,484	¥ 111,076	\$ 1,119,298
Total Assets	687,774	609,352	5,854,888
<b>Per Share Data (Yen/U.S. Dollars):</b>			
Shareholders' Equity	¥ 3,537.89	¥ 3,281.01	\$ 30.117
Net Income	189.55	91.81	1.614
Diluted Net Income	-	-	-
<b>Ratios (%):</b>			
Shareholders' Equity Ratio	19.1	18.2	-
Return on Assets	1.0	0.5	-
Return on Equity	5.8	2.9	-
<b>Cash Flows:</b>			
Net Cash Provided by Operating Activities	¥ 24,665	¥ 10,170	\$ 209,973
Net Cash Used in Investing Activities	(9,992)	(4,039)	(85,063)
Net Cash Used in Financing Activities	(8,555)	(7,567)	(72,831)
Cash and Cash Equivalents at End of the Year	67,436	57,380	574,066
Number of Employees	8,744	7,549	

\* Japanese yen amounts have been translated into U.S. dollars at the rate of U.S.\$1.00=¥117.47.


### Net Sales

(¥ millions)




### Operating Income

(¥ millions)



### Net Income

(¥ millions)



## Key Operating Highlights

SEIWA SANGYO CO., LTD. and Meisho Co., Ltd., whose sales areas cover the Chugoku and Hokuriku regions, respectively, newly joined the Alfresa Group. Furthermore, three companies—OKAUCHI KANKODO, Ltd., Kowa Yakuhin Co., Ltd., and DAIWA Pharmaceutical Wholesalers Co., Ltd.—merged to form Shikoku Alfresa Corporation.

Alfresa Corporation, which conducts the Group's Wholesaling business, concluded a comprehensive business alliance with CS YAKUHIN CO., LTD. and an agreement with KONISHI Medical Instruments CO., LTD. to form an alliance in the supply, processing & distribution (SPD) business.

Alfresa Corporation is building the Meguro Pharmaceuticals Center based on its "Urban Pharmaceuticals Center" concept for creating a pharmaceuticals logistics system in the Tokyo metropolitan area.

Recognizing that one key imperative of the medium- to long-term strategy for the Wholesaling business is to enter Asian markets, the Alfresa Group signed a statement of intent to form a business alliance with DKSH Holding Ltd. Through this alliance, we will begin considering means of developing businesses in Asian markets.

In the Manufacturing business, Alfresa Pharma Corporation began sales of the antidepressant agent Anafranil in the pharmaceutical sector, after taking over production and marketing rights from Novartis Pharma K.K. In the diagnostic reagent sector, the company launched a point-of-care-testing (POCT) reagent to detect influenza virus antigens called CHECK Flu A·B. In medical devices, sales of Monodiox synthetic absorbable surgical sutures were launched.

In the Manufacturing business, ISO13485:2003, the international quality management certification for manufacturers of medical equipment, was obtained by the Chiba Plant, Okayama Pharmaceutical Plant and Ibaraki Research Center. This certification was established to consistently ensure the quality of medical equipment.